Variant CJD in plasma products
Executive Summary
FDA's Transmissible Spongiform Encephalopathies Advisory Committee will discuss risk assessments for potential exposure to variant Creutzfeldt-Jakob disease (vCJD) agent in plasma products at its Feb. 8 meeting. The committee will also consider possible vCJD risk from investigational coagulation Factor XI manufactured in the 1990s from plasma of donors residing in the U.K. and potential deferral of blood and plasma donors for history of transfusion in France and other European countries. The meeting will be held at the Hilton in Silver Spring, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.